Passaro A, Wang J, Wang Y, Lee SH, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced
NSCLC after disease progression on osimertinib: primary results from the phase
III MARIPOSA-2 study. Ann Oncol 2024;35:77-90.
PMID: 37879444